Verseau is developing a new class of cancer immunotherapies that repolarize immuno-suppressive M2 macrophages into pro-inflammatory M1 macrophages, thereby enhancing the immune response against tumors. The company’s proprietary discovery engine has identified over 20 targets for regulating macrophage biology, with two lead programs targeting PSGL-1 and VSIG4 advancing toward clinical trials.
Funding
$69.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In the tumor microenvironment, M2 macrophages suppress the immune system and promote tumor growth, limiting the effectiveness of traditional cancer therapies. Current cancer treatments often fail to adequately address the role of these immunosuppressive macrophages in fostering tumor progression and resistance.
Solution
Verseau is developing a novel class of cancer immunotherapies focused on reprogramming M2 macrophages into pro-inflammatory M1 macrophages, which then stimulate an immune response against tumors. Their approach centers on macrophage repolarization, transforming immunosuppressive cells into active participants in the fight against cancer. Verseau's proprietary discovery engine has identified and validated over 20 targets involved in regulating macrophage biology, enabling the development of targeted therapeutics. The company's lead programs, directed at PSGL-1 and VSIG4, are progressing towards clinical trials. These therapies aim to enhance the body's natural ability to combat cancer by modulating the tumor microenvironment.
Target Audience
The primary target audience includes cancer patients and oncology clinicians seeking novel immunotherapeutic approaches to improve treatment outcomes.
Features
- Proprietary discovery engine for identifying novel macrophage targets
- Focus on repolarizing M2 macrophages into M1 macrophages to stimulate anti-tumor immunity
- Lead programs targeting PSGL-1 and VSIG4
- Development of immunotherapies designed to modulate the tumor microenvironment